期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期或转移性非小细胞肺癌全身治疗进展 被引量：18

晚期或转移性非小细胞肺癌全身治疗进展
原文传递
导出
摘要 晚期和转移性非小细胞肺癌(NSCLC)指Ⅲb或Ⅳ期NSCLC。NSCLC全身化疗后中位总生存期(OS)为7.4个月～9个月,1年生存率31%～43%,客观缓解率(ORR)为20%～40%。采用靶向NSCLC这些异常基因型的小分子化合物和单克隆抗体、反义寡核苷酸、基因治疗显示出疗效,并且毒性较小。
作者 马进元 于鹏 祝毓琳 朱步东
机构地区 承德钢铁集团有限公司职工医院二内科 山东青岛市人民医院肿瘤科 北京大学肿瘤医院暨北京市肿瘤防治研究所日间病房
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2013年第S1期164-166,共3页 Chinese Journal of Practical Internal Medicine
关键词 非小细胞肺癌 治疗 non-small cell lung cancer treatment
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Moran T,Sequist LV.Timing of epidermal growth factor receptortyrosine kinase inhibitor therapy in patients with lung cancerwith EGFR mutations. Journal of Clinical Oncology . 2012
  • 2Makoto M,Akira I,Kunihiko K,et al.Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. The New England Journal of Medicine . 2010
  • 3Oizumi S,Kobayashi K,Inoue A,et al.Quality of life with ge-fitinib in patients with EGFR-mutated non-small cell lungcancer:quality of life analysis of north east Japan study group002trial. The Oncologist . 2012
  • 4Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):a multicentre, open-label,randomised,phase 3 study. The Lancet Oncology . 2011
  • 5Mok TS,Wu YL,Thongprasert S,et al.Gefitinib orcarboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine . 2009
  • 6Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker analyses and final overall survival results from a PhaseⅢ,randomized, open-Label,first-Line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in asia (IPASS). Journal of Clinical Oncology . 2011
  • 7Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,ran-domised phase3trial. The Lancet Oncology . 2010
  • 8Rosell R,Carcereny E,Gervais R.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology . 2012
  • 9Miller VA,Hirsh V,Cadranel J,et al.Afatinib versus place-bo for patients with advanced,metastatic non-small-cell lung cancer after failure of erlotinib,gefitinib,or both,and one or two lines of chemotherapy (LUX-Lung1):a phase2b/3randomised trial. The Lancet Oncology . 2012
  • 10Azzoli CG,Baker S Jr,Temin S, et al.American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. Journal of Clinical Oncology . 2009

同被引文献275

引证文献18

二级引证文献71

中国实用内科杂志
2013年 第S1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部